Repligen Launches CTech SoloVPE PLUS, The Most Advanced UV-based Variable Pathlength System

Repligen

193.69 CHF 12.15%

• Charts
• News
• Analysen

Kaufen / Verkaufen

(RTTNews) - Repligen Corporation (RGEN), a life sciences company, on Monday announced the launch of its CTech SoloVPE PLUS System, an advanced tool for at-line concentration measurement in biological production. The SoloVPE PLUS System uses UV-based Variable Pathlength Technology to provide highly accurate, rapid concentration measurements for biopharmaceutical manufacturers.

The system offers key benefits for the bioprocessing industry, which is increasingly moving toward higher drug concentration formulations. Key updates include:

-- The SoloVPE PLUS System reduces the process steps by 70%, simplifying measurement to just two steps—measure and report.

-- It accelerates acquisition speed, delivering concentration data in half the time of the previous SoloVPE system.

-- The system covers a broad concentration range, including mAbs from 0.01 mg/mL to 320 mg/mL, with a high level of reproducibility (R² = 0.999).

-- CTech ViPER ANLYTX Software integrates SQL for data storage and OPC-UA for standardized communication, enhancing real-time access and scalability.

The SoloVPE PLUS System is designed to meet the growing need for faster, reliable, and accurate tools in the production of biologics, such as antibody-drug conjugates (ADCs) and mRNA-based therapeutics.

"We are excited to launch the SoloVPE PLUS System, which represents the next step in our process analytics capabilities," said Olivier Loeillot, President and CEO of Repligen.

"This product will support manufacturers in making faster, more informed decisions, ultimately improving productivity and reducing time-to-market for biologics."

The SoloVPE PLUS System complements Repligen's existing portfolio, including the FlowVPX System and Real-time Process Management TFF Systems, further strengthening the company's progress in analytical technology.

Repligen is poised to drive continued innovation in bioprocessing technology, with more product launches planned for 2025 to meet the evolving needs of the biopharmaceutical industry.

The company's cash, cash equivalents, and short-term investments were $784 million as of Sep.30, 2024.

RGEN closed Friday's (Jan. 03, 2025) trading at $149.90, up 4.79%. In Premarket trading, the stock is up 0.46% at $150.59